1091TiP STARBOARD: Randomized phase III study of encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for first-line treatment of metastatic or unresectable locally advanced BRAF V600-mutant melanoma
Year: 2021
Type: article
Source: Annals of Oncology
Institutions: University Hospital Zurich, Institut Gustave Roussy, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, Massachusetts General Hospital, University of Tennessee Medical Center, Sarah Cannon, Tennessee Oncology, Florida Atlantic University, Pfizer (United States), Pfizer (Italy), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: bronze
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Gilead Sciences, Array BioPharma, Regeneron Pharmaceuticals, Exelixis, Les Laboratories Pierre Fabre, Astex Pharmaceuticals, Incyte, Syndax Pharmaceuticals, Moderna, Seagen, Eisai, Sun Pharma, Italfarmaco, NeraCare, Genentech, Daiichi Sankyo Europe
OpenAlex ID: W3201664274